Vise Technologies Inc. Acquires New Stake in Koninklijke Philips N.V. $PHG

Vise Technologies Inc. bought a new position in Koninklijke Philips N.V. (NYSE:PHG) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 15,701 shares of the technology company’s stock, valued at approximately $377,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Bank of New York Mellon Corp raised its position in shares of Koninklijke Philips by 6.6% in the 1st quarter. Bank of New York Mellon Corp now owns 59,244 shares of the technology company’s stock worth $1,505,000 after purchasing an additional 3,668 shares during the last quarter. Cerity Partners LLC raised its holdings in Koninklijke Philips by 30.6% in the first quarter. Cerity Partners LLC now owns 80,767 shares of the technology company’s stock worth $2,051,000 after buying an additional 18,906 shares during the last quarter. Carmel Capital Partners LLC lifted its stake in shares of Koninklijke Philips by 6.5% in the first quarter. Carmel Capital Partners LLC now owns 56,457 shares of the technology company’s stock worth $1,434,000 after buying an additional 3,421 shares in the last quarter. Gallacher Capital Management LLC grew its holdings in shares of Koninklijke Philips by 20.2% during the first quarter. Gallacher Capital Management LLC now owns 16,198 shares of the technology company’s stock valued at $411,000 after buying an additional 2,724 shares during the last quarter. Finally, Choreo LLC increased its position in shares of Koninklijke Philips by 4.6% during the first quarter. Choreo LLC now owns 14,530 shares of the technology company’s stock valued at $369,000 after acquiring an additional 633 shares in the last quarter. 13.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PHG has been the subject of several recent analyst reports. Weiss Ratings restated a “hold (c-)” rating on shares of Koninklijke Philips in a research note on Thursday. Wall Street Zen cut shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy”.

Koninklijke Philips Stock Down 1.0%

PHG stock opened at $28.62 on Friday. The business’s 50-day moving average is $28.02 and its two-hundred day moving average is $26.02. The company has a market cap of $27.56 billion, a price-to-earnings ratio of 143.11, a P/E/G ratio of 0.76 and a beta of 0.82. Koninklijke Philips N.V. has a fifty-two week low of $21.48 and a fifty-two week high of $29.54. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.86 and a current ratio of 1.32.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings data on Tuesday, November 4th. The technology company reported $0.37 earnings per share for the quarter, hitting the consensus estimate of $0.37. The firm had revenue of $4.94 billion for the quarter, compared to analysts’ expectations of $4.30 billion. Koninklijke Philips had a net margin of 1.07% and a return on equity of 12.14%. As a group, analysts forecast that Koninklijke Philips N.V. will post 1.63 earnings per share for the current year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.